Lyell Immunopharma, Inc. (LYEL)
22.05
-1.75
(-7.35%)
USD |
NASDAQ |
Mar 05, 16:00
22.16
+0.11
(+0.50%)
Pre-Market: 20:00
Lyell Immunopharma Cash from Investing (Quarterly) : 3.349M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Insmed, Inc. | 389.41M |
| Nektar Therapeutics | -94.87M |
| GT Biopharma, Inc. | 0.00 |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Vertex Pharmaceuticals, Inc. | -288.10M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.58M |
| Cash from Financing (Quarterly) | 50.00M |
| Free Cash Flow | -165.54M |
| Free Cash Flow Per Share (Quarterly) | -1.568 |
| Free Cash Flow to Equity (Quarterly) | -35.12M |
| Free Cash Flow to Firm (Quarterly) | -28.64M |
| Free Cash Flow Yield | -5.05% |